Golnesa ‘GG’ Gharachedaghi, best known from Shahs of Sunset, recently opened up about her unexpected weight loss journey using Ozempic, a drug originally designed to manage type 2 diabetes but now gaining traction for rapid weight loss.
After dropping from 138 pounds to around 110 pounds, Gharachedaghi has decided to cut back on the medication.
Here’s everything you need to know about her experience, side effects she avoided, and what she had to say about societal pressure and personal transformation.
A Look at Golnesa’s Weight Loss Journey
In a candid Instagram video, GG revealed she began taking semaglutide injections (Ozempic) and within months saw dramatic results.
Her starting weight was 138 pounds, and as of April 30, she reported being down to 111 pounds. At that point, she knew it was time to reassess.
“I saw 111 lbs. That’s when I knew, it’s time to cut back,” she said.
Since then, she has moved into a maintenance phase, reducing the dosage of her shots significantly.
Why GG Decided to Cut Back
Golnesa expressed concerns about the unexpected extent of her weight loss, which led her to taper her dosage.
She clarified that while she enjoys how she currently looks and feels, there’s a line between improvement and excess:
“I’m enjoying what it’s doing for me… but I started cutting down on units and going backwards and backwards…”
Despite her success, she acknowledged the possibility of gaining back the weight in the future.
Addressing Common Side Effects of Ozempic
One of the most talked-about side effects of rapid weight loss via Ozempic is “Ozempic face” and “Ozempic butt”, where people experience drooping skin or fat loss in the face and buttocks. GG, however, claims she has been largely unaffected.
“It did not affect my face,” she said. “I haven’t gotten any fillers or Botox recently.”
As for the “Ozempic butt,” she humorously noted:
“I never had an ass… it can’t sag or disappear more than it already was.”
Golnesa’s Message on Body Image and Pressure
While some critics accuse celebrities of promoting unrealistic beauty standards, GG was open about societal pressure and social media influence. She emphasized she’s not encouraging everyone to take this route but is offering insight for those who are already considering it.
She also stated:
“I don’t want to put pressure out there that you should be skinny, but if you want to be, this could help.”
Key Details of Golnesa Gharachedaghi’s Ozempic Journey
| Aspect | Details |
|---|---|
| Starting Weight | 138 lbs |
| Current Weight | ~110-111 lbs |
| Medication Used | Semaglutide (Ozempic) |
| Timeframe | Few months |
| Reason for Cutting Back | Lost more weight than expected |
| Current Plan | Maintenance phase |
| Notable Side Effects Experienced | None reported (no Ozempic face or butt) |
| Public Disclosure Began | March 2024 |
Golnesa Stands by Her Decision
Despite backlash, GG isn’t apologizing for being open about her use of the drug. She’s proud of her transformation and believes in being transparent with her audience.
“I’ve always kept it real. I’m ready to go into a MILF summer.”
She acknowledges that the path she chose may not be right for everyone, but insists it’s been right for her — at least for now.
Golnesa ‘GG’ Gharachedaghi’s journey with Ozempic reflects the growing conversation around weight loss medications and their impacts—both physical and emotional.
Her story highlights the importance of self-awareness, responsibility, and open conversation around body image. While she’s pleased with her current state, her decision to cut back on the drug shows a balanced, health-conscious approach.
FAQs
What medication did GG use for weight loss?
Golnesa used semaglutide, known by brand names such as Ozempic and Wegovy, commonly used for managing type 2 diabetes and weight loss.
How much weight did GG lose?
She lost approximately 28 pounds, dropping from 138 lbs to 110 lbs before entering a maintenance phase.
Did she experience any side effects like “Ozempic face”?
No, she reported no significant side effects, stating her face and body remained largely unaffected.